T-Cell Subtypes from Naive T-Cells

We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab so they will attack cancer cells. If clinical development of the CART T-cell produces the wrong T-cell subtype, patient outcome will suffer. Our T-Cell Subtype cell therapy program aims to improve the efficacy of CAR T-cell therapies.